Evaluation of the Safety, Pharmacokinetics and Efficacy of Three Doses of YN968D1 in Subjects With Solid Tumors.

Trial Profile

Evaluation of the Safety, Pharmacokinetics and Efficacy of Three Doses of YN968D1 in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bukwang Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results assessing preliminary efficacy and safety of apatinib in advanced solid tumors (n=30) presented at the 41st European Society for Medical Oncology Congress.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top